SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

CCCC

C4 Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed11d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EPS beat and cash runway through 2028 are positive, but the revenue decline and lack of near-term catalysts (data not expected until 2H 2027) limit upside. Monitor upcoming investor events (Guggenheim Nov 9, Jefferies Nov 17) for any updates on trial enrollment or partnership milestones.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.95
T+0 close · Nov 5, 2026 · via day close
Latest settled
−6.10%
T+5 · $2.77
Vs SPY
−9.39%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $2.95entry
  2. T+1 · 11d ago +5.08%α +4.77% · $3.10
  3. T+5 · 5d ago −6.10%α −9.39% · $2.77
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

C4 Therapeutics reported Q3 2026 revenue of $8.5M (in line with $8.5M consensus) and a net loss per share of -$0.16, beating the -$0.21 consensus estimate. The company highlighted progress in its cemsidomide clinical program with Phase 2 MOMENTUM trial enrollment on track for Q1 2027 completion and initial ORR data expected in 2H 2027.

Key Financial Metrics

EPS
−$0.16
est −$0.21 · +23.8%
Revenue
$8.5M
est $8.5M · -0.4% · -24.6% YoY
Rating
beat

Key Facts

  • Q3 2026 revenue $8.5M vs $11.2M in Q3 2025, down 24% YoY
  • Q3 2026 net loss per share -$0.16 vs -$0.44 in Q3 2025
  • EPS beat consensus of -$0.21 by 23.8%
  • Cash, cash equivalents and marketable securities $274.7M as of Sep 30, 2026, expected to fund operations to end of 2028
  • Phase 2 MOMENTUM trial enrollment on track to complete in Q1 2027; initial ORR data expected in 2H 2027
  • Phase 1b trial of cemsidomide with elranatamab advancing; data from all cohorts expected mid-2027

Financial Impact

Revenue decline of $2.7M YoY (24%) due to conclusion of certain collaboration activities; net loss improved by $10.4M YoY driven by lower operating expenses and no impairment charge

revenuenet losscash position

Risk Factors

  • Revenue decline of 24% YoY due to reduced collaboration activities
  • Clinical-stage company with no approved products; all value depends on cemsidomide trial outcomes
  • Key data readouts not expected until mid-2027 and 2H 2027, creating a long catalyst gap

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396251

Track record

19 reports on CCCC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
  6. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  7. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  8. Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  9. Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  10. Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026